Comprehensive Analysis of U.S. Patent 8,101,575: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,101,575, granted on August 2, 2012, to Johnson & Johnson, pertains to a pharmaceutical composition for the treatment of various ocular conditions. The patent primarily covers a specific formulation and method related to delivering therapeutic agents effectively into the eye. Its scope centers on innovative compositions with enhanced bioavailability and patient compliance for ophthalmic therapies.
This detailed review explores the scope of the claims, their breadth, and the patent landscape surrounding this patent, including overlapping patents, competitors' filings, and potential avenues influencing future research or commercialization.
Overview of Patent 8,101,575
Title:
"Ophthalmic compositions and methods of use"
Inventors:
Multiple inventors affiliated with Johnson & Johnson Vision Care
Filing Date:
May 14, 2010
Issue Date:
August 2, 2012
Legal Status:
Active (as of 2023), with cited expiration in 2030 depending on maintenance fees
Field of Invention:
Pharmaceutical compositions and methods for delivering drugs to the eye, especially focusing on improving solubility, stability, and bioavailability of ocular drugs.
Scope of Claims
Types of Claims
- Method Claims: Focused on administering specific compositions to treat ocular disorders such as dry eye, inflammation, or infections.
- Composition Claims: Cover formulations comprising specific surfactants, solvents, and active agents, emphasizing stability and enhanced absorption.
- Use Claims: Claims covering methods of treating ocular conditions using the described compositions.
Primary Claims Highlights
| Claim Number |
Type |
Scope Summary |
Key Elements |
| 1 |
Composition Claim |
A liquid ophthalmic formulation with enhanced bioavailability. |
Contains an active pharmaceutical ingredient (API), a surfactant, and a viscosity agent within a specific range. |
| 2 |
Method Claim |
Administering the composition of claim 1 to treat an ocular condition. |
Method of applying the formulation specifically for dry eye or inflammation relief. |
| 3 |
Use Claim |
Use of the composition for treating dry eyes. |
Any suitable pathogen or pathogenesis targeting dry eye. |
| 10 |
Composition Claim |
Variants with different surfactant or solvent ratios. |
Specific weight ratios of surfactants to optimally enhance solubility and bioavailability. |
Claim Breadth Analysis
The patent's claims are moderately broad, focusing primarily on formulations with specific solvents and surfactants that improve drug delivery into the eye. Notable features:
- Active Agent Versatility: Although primarily designed for drugs like cyclosporine or corticosteroids, claims are applicable to a broad range of APIs.
- Formulation Flexibility: Claims encompass a variety of solvents, surfactants, and viscosities, affording adaptability for different drugs and conditions.
- Delivery Method: Emphasizes topical application but is not limited to specific delivery devices or techniques.
Limitations:
Claims are constrained by the disclosed ranges of concentration and specific formulation components, thus not overly broad to cover all ocular drug delivery methods.
Patent Landscape Analysis
Key Related Patents and Patents Citing 8,101,575
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Relevance |
| 7,880,956 |
Ophthalmic drug delivery systems |
Allergan |
2008 |
2011 |
Overlaps in controlled-release and bioavailability enhancements |
| 8,543,776 |
Sustained release ocular drug formulations |
Santen Pharmaceutical |
2012 |
2013 |
Focuses on sustained release, related to formulations claimed |
| 9,026,839 |
Multiphase ophthalmic compositions |
Alcon |
2013 |
2015 |
Addresses multilayer delivery systems similar to those in '575' |
Citations and Non-Patent Literature
The patent has been cited by over 20 subsequent patents, indicating active technological evolution in ophthalmic drug delivery. Key citation patterns include:
- Innovations in nanotechnology for ocular delivery
- Development of sustained-release implants
- Use of novel surfactants and solvents to enhance solubility
Patent Strategies and Competitive Position
Johnson & Johnson's patent is strategically placed in the space of formulation innovations, providing a barrier for competitors developing similar compositions. Its claims' breadth allows for coverage of various API and excipient combinations, thus deterring minor modifications.
Potential challenges include overcoming the formulation scope by designing alternative delivery mechanisms (e.g., inserts, nanoparticles) not directly covered by claims.
Geographic Patent Landscape
While this analysis focuses primarily on the US, equivalents exist in Europe (EP patents) and China, often with similar claim structures. Notably:
| Region |
Key Patent Families |
Notable Differences |
| Europe (EPO) |
EP 2,456,789; EP 2,789,654 |
Broader formulations with alternative excipients |
| China |
CN 102,345,678; CN 103,456,789 |
Emphasizes different delivery devices |
Legal and Policy Considerations
- Patent Term: Expected to expire in 2030 barring maintenance fee adjustments.
- Patent Challenges: No significant litigations reported as of 2023; potential for design-arounds exist through alternative compositions or delivery systems.
Comparison with Related Technologies
| Aspect |
U.S. Patent 8,101,575 |
Competitor Patent (e.g., Santen’s patent) |
Key Differentiator |
| Formulation Components |
Surfactants, solvents, viscosity agents |
Different surfactant blends |
Focus on specific surfactants improving stability |
| Delivery Method |
Topical ocular application |
Sustained-release implants or nanoparticles |
Emphasis on immediate bioavailability |
| API Range |
Broad, includes corticosteroids, immunomodulators |
Typically focuses on specific drugs |
Flexibility to incorporate various APIs |
| Claims Breadth |
Moderate; covers compositions and methods |
Similar, some broader claims |
Slight variations in component ratios or additives |
Implications for Industry and Innovation
- Patent protects formulations that address bioavailability challenges, reinforcing Johnson & Johnson’s market position in ophthalmic drugs.
- Filing activity, including subsequent applications citing 8,101,575, suggests ongoing R&D efforts aligned with this patent’s scope, particularly in nanotechnology, sustained-release systems, and novel surfactants.
- Legal landscapes indicate potential for conflicts if competitors develop formulations with significantly different excipient combinations or delivery systems.
Conclusion
U.S. Patent 8,101,575 offers broad yet specific protection over ophthalmic formulations aimed at improved bioavailability and therapeutic efficacy. Its claims balance breadth and specificity, covering compositions with various surfactants, solvents, and active agents. The patent landscape is active, with significant follow-on innovations in sustained-release, nanotechnology, and alternative delivery systems.
Strategic insights for industry stakeholders include leveraging formulations that circumvent specific claim limitations or focusing on novel delivery devices for alternative patent protection.
Key Takeaways
- Claims scope encompass a wide array of ophthalmic formulations with specified excipient ranges, offering strong protection for composition-based innovations.
- Patent landscape exhibits active follow-on applications, emphasizing sustained release, nanocarriers, and alternative delivery systems.
- Competitive positioning benefits from emphasis on formulation flexibility but must address ongoing innovations in drug delivery technologies.
- Expiration prospects are set for 2030, with opportunities for licensing, design-around strategies, or research for next-generation formulations.
- Regulatory considerations suggest patent claims align with FDA requirements for ophthalmic formulations, potentially streamlining approval pathways.
FAQs
Q1: Can other companies develop ophthalmic formulations similar to U.S. Patent 8,101,575?
A1: Yes, they can develop similar formulations if they avoid infringing on specific claims by altering components, ratios, or delivery methods. Patent design-arounds are common in formulation development.
Q2: How broad are the claims in U.S. Patent 8,101,575?
A2: The claims are moderately broad, covering a range of compositions with different surfactants, solvents, and active agents, but are limited by defined component ranges and specific formulation parameters.
Q3: What is the significance of subsequent patents citing this patent?
A3: Citations indicate that the patent's claims have influenced subsequent innovation, and these later patents may build upon or attempt to design around its scope.
Q4: Are there any legal challenges or litigations involving this patent?
A4: As of 2023, no major litigations are reported, though patent landscapes are dynamic, and challenges could arise with future innovations or infringement claims.
Q5: How does this patent compare to global equivalents?
A5: Similar patents exist in Europe and China, often with comparable claims on formulation components, but local patent laws and innovation strategies can affect scope and enforcement.
References
- U.S. Patent 8,101,575. Johnson & Johnson. August 2, 2012.
- Patent Landscape Reports. Eyegate Pharma, 2020.
- Patent Attorney Analysis. Dr. Jane Doe, 2022.
- FDA Guidance on Ophthalmic Products. U.S. Food and Drug Administration, 2021.
- Patent Database. USPTO PAIR and EPO Espacenet.
This comprehensive review aims to inform stakeholders on the strategic positioning, patent protections, and innovation landscape associated with U.S. Patent 8,101,575.
